MNLO - Menlo Therapeutics Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.3500
+0.2200 (+5.33%)
At close: 4:00PM EST

4.3500 0.00 (0.00%)
After hours: 4:00PM EST

Stock chart is not supported by your current browser
Previous Close4.1300
Open4.2000
Bid4.3600 x 900
Ask4.5000 x 1000
Day's Range4.1500 - 4.4299
52 Week Range2.6900 - 9.0310
Volume27,456
Avg. Volume58,385
Market Cap104.33M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.9600
Earnings DateOct 31, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.83
  • GlobeNewswire

    Menlo Therapeutics CEO to Participate in Fireside Chat at the Piper Jaffray 31st Annual Healthcare Conference

    Menlo Therapeutics Inc. (MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steve Basta, chief executive officer of Menlo Therapeutics, will provide a corporate update via a fireside chat at the Piper Jaffray 31st Annual Healthcare Conference to be held in New York on December 03, 2019 at 4:00 pm ET. The fireside chat will be webcast live and can be accessed by logging onto the “Investors” section of the Menlo Therapeutics website at www.menlotherapeutics.com. Menlo Therapeutics Inc. is a late-stage biopharmaceutical company focused on the development of serlopitant, a once-daily oral NK1 receptor antagonist, for the treatment of pruritus.

  • GlobeNewswire

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Merger of Menlo Therapeutics Inc. with Foamix Pharmaceuticals Ltd. is Fair to MNLO Shareholders

    NEW YORK, Nov. 13, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Menlo Therapeutics Inc. (“Menlo” or.

  • SHAREHOLDER ALERT: WeissLaw LLP Investigates Foamix Pharmaceuticals Ltd.
    PR Newswire

    SHAREHOLDER ALERT: WeissLaw LLP Investigates Foamix Pharmaceuticals Ltd.

    NEW YORK , Nov. 12, 2019 /PRNewswire/ -- WeissLaw LLP  is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Foamix Pharmaceuticals Ltd. ("FOMX" ...

  • MarketWatch

    Menlo, Foamix stocks set for selloffs after all-stock merger deal

    Shares of Menlo Therapeutics Ltd. was indicated down 14% in premarket trading Monday, and Foamix Pharmaceuticals Ltd. plunged 16%, after the company's announced a merger in which Foamix acquired Menlo in an all-stock deal. Under terms of the deal, each Foamix share will be exchanged for 0.5924 shares of Menlo common stock and a contingent stock right (CSR), which the companies said implies an 18% premium to Menlo's shareholders, based on the 10-day average volume-weighted price. Foamix shareholders will own 59% of the combined company. Menlo's lead product candidate, serlopitant, is being developed as a novel treatment for pruritus (itch), and Foamix's acne treatment Amzeeq has been approved by the Food and Drug Administration. If one of two of the phase 3 trials for serlopitant fails to meet its primary endpoint by May 31, 2020, Foamix shareholders will receive an additional 0.6815 of Menlo shares for each Foamix stock they own. If both phase 3 trials miss the primary endpoints, Foamix shareholders will receive an additional 1.2082 Menlo shares. Shares of Foamix have run up 56% over the past three months and Menlo soared 67%, while the S&P 500 has gained 6.0%.

  • GlobeNewswire

    Foamix and Menlo Therapeutics to Merge, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications

    Foamix Pharmaceuticals Ltd. (FOMX) (“Foamix”) and Menlo Therapeutics Inc. (MNLO) (“Menlo”) today announced that they have signed a definitive merger agreement to create a combined biopharmaceutical company focused on the commercialization and development of therapeutics to serve patients in the dermatology space. The Boards of Directors of both Foamix and Menlo have unanimously approved the transaction.

  • GlobeNewswire

    Menlo Therapeutics Reports Third Quarter 2019 Financial Results and Provides Program Updates

    Menlo Therapeutics Inc. (MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced financial results for the third quarter ended September 30, 2019 and provided an update on its clinical development programs. “We are in a period of tremendous momentum in the development of serlopitant with the rapid completion of enrollment in our two Phase 3 trials in prurigo nodularis and our Phase 2 trial in chronic pruritus of unknown origin, which reflects our team’s strong execution as well as an abundance of patients and physicians motivated to participate in our trials,” said Steve Basta, chief executive officer of Menlo Therapeutics.

  • GlobeNewswire

    Menlo Therapeutics Announces Completion of Enrollment in Two Phase 3 Trials of Serlopitant in Prurigo Nodularis

    Menlo Therapeutics Inc. (MNLO), a late-stage biopharmaceutical company, today announced that it has completed enrollment of patients in its two Phase 3 clinical trials evaluating the safety and efficacy of once daily oral serlopitant for the treatment of pruritus associated with prurigo nodularis (PN). The U.S. and European Phase 3 trials enrolled 285 and 295 patients, respectively.  The Phase 3 trials are designed to evaluate reduction in pruritus in patients treated with serlopitant compared to placebo over a ten-week treatment period.  The primary endpoint in these studies will compare the number of treated vs. control patients who experience a 4-point improvement on the worst-itch numeric rating scale (WI-NRS), which is a standard measure of itch.  Serlopitant has received Breakthrough Therapy Designation by the FDA for the treatment of pruritus associated with PN, a severely itchy skin disease characterized by multiple, firm, itchy nodules on the skin.

  • GlobeNewswire

    Menlo Therapeutics to Host Investor Day October 29, 2019

    Menlo Therapeutics Inc. (MNLO), a late-stage biopharmaceutical company, announced that the company will host an Investor Day on Tuesday, October 29th, 8:00–11:00 am ET. The event will focus on a review of Menlo’s clinical programs, regulatory plans, and potential commercial opportunities for serlopitant in multiple pruritus indications. Two key opinion leaders: Dr. Sonja Ständer, M.D., Head of the Center for Chronic Pruritus at the University of Munster and Dr. Gil Yosipovitch, M.D., Professor at the University of Miami Miller School of Medicine and Director of the Miami Itch Center, will provide clinician perspectives on the unmet need of treating pruritus associated with prurigo nodularis and chronic pruritus of unknown origin.

  • Here's Why We're Watching Menlo Therapeutics's (NASDAQ:MNLO) Cash Burn Situation
    Simply Wall St.

    Here's Why We're Watching Menlo Therapeutics's (NASDAQ:MNLO) Cash Burn Situation

    We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

  • GlobeNewswire

    Menlo Therapeutics Presents Successful Phase 2 Clinical Trial Results of Serlopitant in Psoriasis at the European Academy of Dermatology and Venereology Meeting

    Menlo Therapeutics Inc. (MNLO), a late-stage biopharmaceutical company, presented results from its successful Phase 2 clinical trial of serlopitant for the treatment of pruritis in patients with psoriasis in an oral presentation at the 28th Congress of the European Academy of Dermatology and Venereology held in Madrid yesterday.  The results demonstrated a statistically significant reduction in pruritis (itch) in patients treated with serlopitant, compared to placebo, and further demonstrated consistent benefit favoring serlopitant when evaluating response rates across patient demographic categories assessed in this study.  Pruritis is reported by patients to be one of the most severe and troublesome symptoms of psoriasis. The psoriasis trial reported at EADV successfully met its primary endpoint, showing a statistically significant reduction in pruritus based upon a 4-point improvement responder analysis.  In the trial, 33% of patients treated with serlopitant 5 mg daily achieved a 4-point or greater improvement on the worst-itch numeric rating scale, or WI-NRS, at week 8 compared to baseline vs. 21% of patients treated with placebo (primary efficacy endpoint, p= 0.028). Additionally, the 4-point responder rate at week 8 was higher in serlopitant-treated patients than in patients in the placebo group when evaluating groups segmented by baseline characteristics:  age, gender, weight, percentage of body surface area affected by psoriasis lesions, itch severity, or severity of psoriasis.

  • GlobeNewswire

    Menlo Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

    Menlo Therapeutics Inc. (MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steven Basta, chief executive officer of Menlo Therapeutics, will present at the 2019 Cantor Global Healthcare Conference to be held in New York on October 4, 2019 at 9:30 am ET. The presentation will be webcast live and can be accessed by logging onto the “Investors” section of the Menlo Therapeutics website at www.menlotherapeutics.com.  A replay of the webcast will be archived on the company’s website for 30 days following the presentation. Menlo Therapeutics Inc. is a late-stage biopharmaceutical company focused on the development of serlopitant, a once-daily oral NK1 receptor antagonist, for the treatment of pruritus.

  • Menlo (MNLO) Completes Enrollment in Phase II Pruritus Study
    Zacks

    Menlo (MNLO) Completes Enrollment in Phase II Pruritus Study

    Menlo (MNLO) completes enrollment in the phase II study evaluating the safety and efficacy of once-daily oral serlopitant for the treatment of CPUO.

  • GlobeNewswire

    Menlo Therapeutics Announces Completion of Enrollment of 233 Patients in Phase 2 Trial of Serlopitant in Patients with Chronic Pruritus of Unknown Origin

    Menlo Therapeutics Inc. (MNLO), a late-stage biopharmaceutical company, today announced that it has completed patient enrollment in its Phase 2 clinical trial evaluating the safety and efficacy of once daily oral serlopitant for the treatment of Chronic Pruritus (itch) of Unknown Origin (CPUO). The Phase 2 trial is designed to evaluate reduction in pruritus with serlopitant compared to placebo over a ten-week treatment period based upon a 4-point responder analysis on the worst-itch numeric rating scale (WI-NRS), which is a standard measure of itch.  CPUO is a condition in which patients suffer from itch, often for years, without any identified medical condition as a cause for the itch.  This condition may affect approximately two million patients in the U.S., with no therapy approved or indicated to treat these patients.

  • GlobeNewswire

    Menlo Therapeutics to Present at the HC Wainwright 21st Annual Global Investment Conference

    Menlo Therapeutics Inc. (MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Kristine Ball, chief financial officer of Menlo Therapeutics, will present at the HC Wainwright 21st Annual Global Investment Conference to be held in New York on September 9, 2019 at 12:05 PM EDT. The presentation will be webcast live and can be accessed by logging onto the “Investors” section of the Menlo Therapeutics website at www.menlotherapeutics.com.  A replay of the webcast will be archived on the company’s website for 30 days following the presentation. Menlo Therapeutics Inc. is a late-stage biopharmaceutical company focused on the development of serlopitant, a once-daily oral NK1 receptor antagonist, for the treatment of pruritus.

  • GlobeNewswire

    Menlo Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference

    The presentation will be webcast live and can be accessed by logging onto the “Investors” section of the Menlo Therapeutics website, www.menlotherapeutics.com, prior to the event.  A replay of the webcast will be archived on the Company’s website for 30 days following the presentation. Menlo Therapeutics Inc. is a late-stage biopharmaceutical company focused on the development of serlopitant, a once-daily oral NK1 receptor antagonist, for the treatment of pruritus.

  • Did You Manage To Avoid Menlo Therapeutics's (NASDAQ:MNLO) 42% Share Price Drop?
    Simply Wall St.

    Did You Manage To Avoid Menlo Therapeutics's (NASDAQ:MNLO) 42% Share Price Drop?

    It's easy to match the overall market return by buying an index fund. But if you buy individual stocks, you can do...

  • CNW Group

    Life Science Company Live Investor Presentations Now Available for On-Demand Viewing

    Life Science Company Live Investor Presentations Now Available for On-Demand Viewing

  • PR Newswire

    Life Science Company Live Investor Conference July 11th

    Life science company executives will share vision and answer audience questions at VirtualInvestorConferences.com NEW YORK , July 9, 2019 /PRNewswire/ -- Virtual Investor Conferences today announced the ...

  • Is Menlo Therapeutics Inc. (MNLO) A Good Stock To Buy ?
    Insider Monkey

    Is Menlo Therapeutics Inc. (MNLO) A Good Stock To Buy ?

    A market surge in the first quarter, spurred by easing global macroeconomic concerns and Powell's pivot ended up having a positive impact on the markets and many hedge funds as a result. The stocks of smaller companies which were especially hard hit during the fourth quarter slightly outperformed the market during the first quarter. Unfortunately, […]

  • GlobeNewswire

    Menlo Therapeutics Announces Addition of Ronald A. Krasnow as General Counsel and Chief Compliance Officer

    REDWOOD CITY, Calif., June 18, 2019 -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the.

  • GlobeNewswire

    Menlo Therapeutics to Present at Upcoming Investor Conferences

    The presentations will be webcast live and can be accessed by logging onto the “Investors” section of the Menlo Therapeutics website, www.menlotherapeutics.com, prior to the event. Menlo Therapeutics Inc. is a late-stage biopharmaceutical company focused on the development of serlopitant, a once-daily oral NK1 receptor antagonist, for the treatment of pruritus.

  • GlobeNewswire

    EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Menlo Therapeutics, Inc. of Class Action Lawsuit

    To: All persons or entities who purchased or otherwise acquired securities of Menlo Therapeutics, Inc. (“Menlo” or the “Company”) (MNLO) pursuant or traceable to the Company’s Initial Public Offering closed on January 29, 2018. If you purchased or otherwise acquired Menlo securities pursuant to the initial public offering, your rights may be affected by this action. In its January 2018 IPO, Menlo issued over 8 million shares at $17 per share, raising over $136 million in gross proceeds.